370
Participants
Start Date
October 30, 2024
Primary Completion Date
May 30, 2026
Study Completion Date
October 30, 2026
Semaglutide
The dose escalation phase, starting with 0.25mg once weekly and increasing every 4 weeks (0.5mg, 1.0mg, 1.7mg), is expected to last 16 weeks; In the dose maintenance phase, the target dose of 2.4mg was maintained for 28 weeks.Treatment duration 44 weeks.
Semaglutide
The dose escalation phase, starting with 0.25mg once weekly and increasing every 4 weeks (0.5mg, 1.0mg, 1.7mg), is expected to last 16 weeks; In the dose maintenance phase, the target dose of 2.4mg was maintained for 28 weeks.Treatment duration 44 weeks.
Xuancheng People's Hospital, Xuancheng
Huizhou Central People's Hospital, Huizhou
Luoyang Third People's Hospital, Luoyang
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang
The First Affiliated Hospital of Nanyang Medical College, Nanyang
The Second Affiliated Hospital of Zhengzhou University, Zhengzhou
Yichang Central People's Hospital, Yichang
Huai an First People's Hospital, Huaian
The Second People's Hospital of Lianyungang, Lianyungang
The Second Affiliated Hospital of Nanjing Medical University, Nanjing
The First Affiliated Hospital of Soochow University, Suzhou
Affiliated Hospital of Jiangsu University, Zhenjiang
Central Hospital Affiliated to Shandong First Medical University, Jinan
Jincheng Grand Hospital, Jincheng
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
INDUSTRY